Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
King Abdullah International Medical Research Center (KAIMRC) has been spearheading an initiative to advance clinical trials in the kingdom to help provide the Saudi population with treatment that is specific to their genomics and to the diseases that are prevalent in the population. The goal is to increase the proportion of phase I, II and III clinical trials from the current six, to 100 trials for every 1,000 doctors and provide free treatment for 10,000 patients within the next 10 years, generating 5,000 new jobs.
The kingdom will host its first phase I clinical trial in late 2019 or early 2020, testing a potential vaccine for the Middle East respiratory syndrome corona virus (MERS-CoV) that they developed in cooperation with Oxford University. KAIMRC has an extensive record of research on MERS-CoV, a disease that has affected more than 200 people in Saudi Arabia this year and has a mortality rate as high as 50%. A 2015 MERS-CoV outbreak in Saudi Arabia, which affected around 130 patients, led KAIMRC to prioritize MERS-CoV research as a strategic project.
MERS-CoV, however regionally strategic, is only one area of research that KAIMRC believes is crucial to the Saudi population. They are also conducting studies on diseases that are prevalent in the kingdom, but that are often researched on other populations and genomes, such as heart disease, a major killer in Saudi Arabia, and diabetes. We look at some of the key research at the centre over the past year, from its first phase I clinical trial, to their research on superbugs in the kingdom.
Produced for KAIMRC by Nature Research Custom Media.
The medical hub’s research into a single-dose vaccine for the lethal Middle East respiratory syndrome coronavirus (MERS-CoV) is promising, but more evaluation and trials are needed, scientists say.
A case of a rare childhood disease reveals a new mutation as underlying cause and identifies unknown manifestations of the disease on the skin and hair.